Gentian Diagnostics AS (GENT)

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and canine CRP immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also provides SARS-CoV-2 total antibody immunoassay, quantitative antibody test captures the full immune response detecting antibodies targeting the S1-subunit. In addition, the company develops NT-proBNP Immunoassay, an aid in the diagnosis, monitoring and assessment of severity in individuals suspected of having congestive heart failure which is in product development phase. Further, it offers faecal calprotectin immunoassay, provides results of calprotectin in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. The company was founded in 2001 and is headquartered in Moss, Norway.